Abstract
Background and aimsLiraglutide treatment can improve glycemic control with a concomitant weight loss, but the underlying mechanism on weight loss is not completely understood. Cardiac natriuretic peptides (NPs) can resist body fat accumulation through increasing adipocytes lypolysis. In this study, we tested the hypothesis that liraglutide-induced weight loss was associated with increased plasma NPs concentrations.MethodsThirty-one outpatients with type 2 diabetes (T2D) treated with metformin and other oral antidiabetic drugs except for thiazolidinediones (TZDs) were subcutaneously administered with liraglutide for 12 weeks. Body composition, abdominal visceral adipose tissue areas (VAT) and subcutaneous adipose tissue areas (SAT) were assessed at pre- and post-treatment by dual-energy X-ray absorptiometry (DXA) scanning and abdominal computerized tomography (CT). Plasma atrial natriuretic peptides (ANP) and B-type ventricular natriuretic peptides (BNP) concentrations were tested by commercial ELISA Kit quantitatively.ResultsFollowing 12-week liraglutide treatment, body weight, waist circumference, total fat and lean mass, fat percentage, SAT and VAT areas were significantly reduced from baseline. Concurrently, plasma ANP and BNP levels were significantly increased following 12-week liraglutide treatment. There were significant correlations between the reductions in body compositions and the increases in both plasma ANP and BNP levels.ConclusionsThere were significant correlations between increases in both plasma ANP and BNP levels and changes in liraglutide-induced body composition. Our data implied that increases in plasma NPs may add a novel dimension to explain how liraglutide induces weight loss.
Highlights
The prevalence of obesity and diabetes has rapidly increased worldwide including Western and Asian countries, it is estimated that 80% of type 2 diabetic patients are obese [1]
The dual-energy X-ray absorptiometry (DXA) and computerized tomography (CT) assessments have shown that reductions in body weight with liraglutide primarily come from reductions in fat mass rather than lean tissue mass, abdominal visceral fat tissues (VAT) reduced greater than subcutaneous fat tissues (SAT) [7]
We recently reported that liraglutide treatment led to a mean reduction in body weight of 5.62 kg in Chinese obese type 2 diabetes (T2D) [8], much greater than reported in Liraglutide Effect and Action in Diabetes (LEAD)-2 and LEAD-3 studies [5,6], but the effect of liraglutide-induced weight loss on body composition has not been observed in Chinese T2D
Summary
The prevalence of obesity and diabetes has rapidly increased worldwide including Western and Asian countries, it is estimated that 80% of type 2 diabetic patients are obese [1]. In China, the combined prevalence of overweight and obesity has increased nearly 50% in a 10-y period [2]. In this sense, it is necessary to develop hypoglycemia [5,6]. We recently reported that liraglutide treatment led to a mean reduction in body weight of 5.62 kg in Chinese obese T2D [8], much greater than reported in LEAD-2 and LEAD-3 studies [5,6], but the effect of liraglutide-induced weight loss on body composition has not been observed in Chinese T2D. The underlying mechanism on liraglutide-induced weight loss is not completely understood. Liraglutide treatment can improve glycemic control with a concomitant weight loss, but the underlying mechanism on weight loss is not completely understood. We tested the hypothesis that liraglutide-induced weight loss was associated with increased plasma NPs concentrations
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
